5 Sep 2021
New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps
Author: admintech | Filed under: Press ReleaseTHOUSAND OAKS, Calif., Sept. 5, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new data from the pivotal NAVIGATOR Phase 3 trial demonstrating that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and…